Recently, DPP-IV inhibitors are used as a novel way to augment the incretin system and one of
the newest classes of medications in the treatment of type 2 diabetes mellitus (T2DM). Since
the DPP-IV inhibitor was first used, about 5 years have passed in USA. However, there were no
major side effects including occurrence of cancers. The main mechanism for DPP-IV inhibitors
is due to suppress the function of DPP-IV activity. As it is known that the suppressed DPP-IV
activity is a marker for early diagnosis of cancers, the reason of disassociation is not
Activation of receptor for advanced glycation endproduct (AGE) is related to sideration of
cancers. Meanwhile, the DPP-IV inhibitors may be related to inhibit the activation of
receptor for AGE (RAGE). Therefore, DPP-IV inhibitors may work as a cancer protective agent
in diabetes by blocking the AGE-RAGE axis.
However, it is not demonstrated why DPP-IV inhibitors have no side effect of occurrence of
cancer via blocking the activation of AGE-RAGE.
The investigators examined effect of DPP-IV inhibitors on frequency of cancers and the
underlying mechanism using AGE and RAGE before and 5 years after administration of DPP-IV
inhibitors in Japanese patients with T2DM.